Alcresta Revenue and Competitors
Estimated Revenue & Valuation
- Alcresta's estimated annual revenue is currently $17.1M per year.
- Alcresta's estimated revenue per employee is $251,000
Employee Data
- Alcresta has 68 Employees.
- Alcresta grew their employee count by 1% last year.
Alcresta's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Research and New Product Development | Reveal Email/Phone |
3 | Director | Reveal Email/Phone |
4 | Chief Commercial Officer | Reveal Email/Phone |
5 | Senior Director | Reveal Email/Phone |
6 | Senior Director Regulatory Affairs | Reveal Email/Phone |
7 | Associate Director Program Management | Reveal Email/Phone |
8 | Associate Director, Product Management | Reveal Email/Phone |
9 | Chief Legal Officer | Reveal Email/Phone |
10 | Director Finance | Reveal Email/Phone |
Alcresta Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $9.8M | 39 | 3% | N/A | N/A |
#2 | $8.5M | 34 | 3% | N/A | N/A |
#3 | $3M | 12 | -29% | N/A | N/A |
#4 | $5630M | 7477 | -11% | $450M | N/A |
#5 | $4.5M | 18 | 6% | N/A | N/A |
#6 | $7.2M | 57 | 27% | $29.6M | N/A |
#7 | $14.3M | 57 | -12% | N/A | N/A |
#8 | $2.3M | 18 | 6% | $44M | N/A |
#9 | $40.7M | 162 | -1% | N/A | N/A |
#10 | $45.7M | 182 | -5% | N/A | N/A |
What Is Alcresta?
Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company's lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company's platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.
keywords:N/A
N/A
Total Funding
68
Number of Employees
$17.1M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alcresta News
Alcresta announced its first profitable year in 2021, the completion of royalty payments to the Cystic Fibrosis Foundation (CFF) and a doubling...
Other Companies in Newton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.3M | 70 | 0% | N/A |
#2 | $17.3M | 71 | 3% | N/A |
#3 | $10.6M | 72 | -15% | $6.3M |
#4 | $16.5M | 73 | 26% | N/A |
#5 | $9.5M | 75 | -3% | N/A |